| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265737 | NEOS THERAPS INC | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US8709491 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
| US9017731 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
Adzenys Er is owned by Neos Theraps Inc.
Adzenys Er contains Amphetamine.
Adzenys Er has a total of 3 drug patents out of which 0 drug patents have expired.
Adzenys Er was authorised for market use on 15 September, 2017.
Adzenys Er is available in suspension, extended release;oral dosage forms.
The generics of Adzenys Er are possible to be released after 28 June, 2032.
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 15 September, 2017
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
More Information on Dosage
ADZENYS ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic